Ali H, Loizidou M, Dashwood M, Savage F, Sheard C, Taylor I
Department of Surgery, Royal Free and University College Medical School, London, UK.
Gut. 2000 Nov;47(5):685-8. doi: 10.1136/gut.47.5.685.
The vasoactive peptide endothelin 1 (ET-1) acts via two receptors, endothelin receptors A (ET(A)) and B (ET(B)). ET-1 is overexpressed by human cancers in vivo and in vitro and may be mitogenic for cancer cells.
To elucidate if ET-1 is a growth regulator the following were investigated in human colorectal cancer cell lines (LIM1215 and HT29): ET-1 production by ELISA; ET receptor expression using radioligand autoradiographic techniques; and responsiveness to ET-1, and to ET(A) and ET(B) antagonism by growth measurements.
ET-1 was produced by LIM1215 and HT29 cells (21.3 and 41.7 fmol/ml/10(6) cells (24 hours); 22.6 and 71.7 fmol/ml/10(6) cells (48 hours), respectively). ET(A) and ET(B) receptors were expressed by both cell lines. Addition of ET-1 resulted in a dose dependent increase in cell numbers which was significant at 10(-8)-10(-9) M for LIM1215, with the greatest increase at 10(-8) M (32.7% and 28.4% increase above controls at 48 hours and 72 hours; p<0.05) and at 10(-8)-10(-9) M for HT29, with the greatest increase at 10(-9) M (13.4% and 15.7% increase above controls at 48 hours and 72 hours; p<0.05). ET(A) antagonists BQ123 and BQ610, but not the ET(B) antagonist BQ788, inhibited ET-1 induced proliferation of both LIM1215 and HT29 (p<0.05).
ET-1 can stimulate the proliferation of colorectal cancer cell lines via the ET(A), but not the ET(B), receptor.
血管活性肽内皮素1(ET-1)通过两种受体发挥作用,即内皮素受体A(ET(A))和B(ET(B))。ET-1在体内和体外的人类癌症中均过度表达,且可能对癌细胞具有促有丝分裂作用。
为阐明ET-1是否为生长调节因子,在人结肠癌细胞系(LIM1215和HT29)中进行了以下研究:采用酶联免疫吸附测定法检测ET-1的产生;运用放射性配体放射自显影技术检测ET受体的表达;通过生长测量评估对ET-1以及ET(A)和ET(B)拮抗剂的反应性。
LIM1215和HT29细胞均可产生ET-1(分别为21.3和41.7 fmol/ml/10⁶细胞(24小时);22.6和71.7 fmol/ml/10⁶细胞(48小时))。两种细胞系均表达ET(A)和ET(B)受体。添加ET-1导致细胞数量呈剂量依赖性增加,对于LIM1215,在10⁻⁸ - 10⁻⁹ M时具有显著增加,在10⁻⁸ M时增加最为明显(48小时和72小时时比对照增加32.7%和28.4%;p<0.05);对于HT29,在10⁻⁸ - 10⁻⁹ M时增加显著,在10⁻⁹ M时增加最为明显(48小时和72小时时比对照增加13.4%和15.7%;p<0.05)。ET(A)拮抗剂BQ123和BQ610可抑制ET-1诱导的LIM1215和HT29增殖(p<0.05),但ET(B)拮抗剂BQ788无此作用。
ET-1可通过ET(A)受体而非ET(B)受体刺激结肠癌细胞系的增殖。